Enimmune

Enimmune EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Enimmune (6564.TWO) as of Oct 27, 2026 is -9.95. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.22 — a change of 37.76% (lower).

EV/FCF

-9.95

YoY

37.76%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Enimmune is 2025 -9.95 . EV/FCF (Enterprise Value to Free Cash Flow) of Enimmune was 2024 -7.22 . It decreases by 37.76% lower compared to the previous year.

The Enimmune EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-14.12 TWD
Jan 1, 2019
-21.25 TWD
Jan 1, 2020
-9.13 TWD
Jan 1, 2021
-14.64 TWD
Jan 1, 2022
-4.81 TWD
Jan 1, 2023
-8.00 TWD
Jan 1, 2024
-7.22 TWD
Jan 1, 2025
-9.95 TWD
The Enimmune EV/FCF history
YEAREV/FCFYoY
-9.95+37.76%
-7.22-9.69%
-8.00+66.32%
-4.81-67.15%
-14.64+60.28%
-9.13-57.01%
-21.25+50.47%
-14.12+13.58%
-12.43-19.34%
-15.41-35.27%
-23.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enimmune Stock analysis

What does Enimmune do? Enimmune Corp. generates revenue through the development and sale of new drug products, including biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The company conducts drug testing, biotechnology services, international trade, and western medicine wholesale and retail. Its primary product, Tuberculin PPD, is sold in the pharmaceutical market. The firm targets healthcare providers, research institutions, and pharmaceutical distributors as key customers for its drug development and testing services. The company's business model focuses on the research, development, and commercialization of innovative drug solutions. Drug testing services are provided to pharmaceutical and biotech firms, while biotechnology services support research and development activities. International trade and western medicine wholesale operations further contribute to revenue streams. Tuberculin PPD serves as a core product for the company's pharmaceutical sales. Enimmune Corp. operates within the pharmaceutical sector, leveraging its drug development expertise to serve healthcare and biotechnology markets. The firm's revenue streams are derived from multiple business segments, including drug development, testing, biotechnology services, and pharmaceutical distribution. The company's product portfolio centers on Tuberculin PPD and its range of new drug products. Enimmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enimmune stock

EV/FCF (Enterprise Value to Free Cash Flow) of Enimmune is -9.95 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Enimmune changed from -7.22 to -9.95, representing a 37.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Enimmune since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Enimmune with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Enimmune

All Key Metrics — Enimmune